StructurE-unbiased Library for Exploratory disCovery of Targets
StructurE-unbiased Library for Exploratory disCovery of Targets
A multidisciplinary team driving innovation in antiviral and anticancer drug discovery.
The SELECT platform is powered by a dedicated team of scientists, technicians, and collaborators from KU Leuven’s Rega Institute. Together, we combine expertise in medicinal chemistry, virology, oncology, genetic engineering, and high-throughput screening to accelerate therapeutic discovery.
Dr. Steven De Jonghe
Project Manager – Medicinal Chemist
Leads compound library development and external collaborations.
Ing. Leentje Persoons
Senior Scientist
Oversees screening campaigns and biological data generation.
Prof. Dirk Daelemans
Principal Investigator
Expert in CRISPR-based target deconvolution and cancer biology.
Prof. Christophe Pannecouque
Principal Investigator
Specialist in virus biology and medicinal chemistry.
Joni Punjwani
Oversees the execution of high-throughput antitumoral screening assays across our cancer cell line panel.
Yanicka Smolders
Runs the antiviral screening campaigns and manages the registration and tracking of incoming compounds.
Nathalie Van Winkel
Leads antitumoral target deconvolution studies, combining computational target prediction and common mechanism exclusion.
Niels Willems
Performs advanced antiviral deconvolution assays to uncover mechanisms of action behind promising compounds.
Our team collaborates closely with virology and oncology labs, chemists, and proteomics experts across KU Leuven and beyond. We believe in the power of interdisciplinary science to drive disruptive discoveries.